摘要
目的探讨布地奈德对慢性阻塞性肺病(COPD)患者基质金属蛋白酶-9及其抑制物-1水平的影响。方法选择COPD患者76例,随机分为2组。两组患者均常规予以低流量吸氧、抗感染、解痉平喘及止咳化痰等对症治疗。观察组在此基础上加用布地奈德混悬液雾化吸入2 mL/次,2次/d,连用1周。观察并比较两组患者治疗前和治疗1周后血清MMP-9、TIMP-1水平及MMP-9/TIMP-1比值的变化,并进行临床疗效及安全性评价。结果治疗1周后,两组患者血清MMP-9、TIMP-1水平及MMP-9/TIMP-1比值均下降(P<0.05),且观察组下降的幅度均较对照组更明显(P<0.05);观察组的临床总有效率明显高于对照组(P<0.05);两组患者治疗期间均未发生明显的药物不良反应。结论布地奈德雾化吸入治疗COPD具有较好的临床疗效及安全性,作用机制与下调MMP-9、TIMP-1水平和MMP-9/TIMP-1比值、抑制气道重塑过程密切相关。
Objective To discuss the effect of budesonide on MMP-9 and TIMP-1 levels of patients with chro- nic obstructive pulmonary disease(COPD). Methods 76 patients with COPD were divided into observation group and control group randomly. Patients in the two groups were given routine symptomatic treatment, such as oxygen uptake with low flow, anti-infection, spasmolysis and relieving asthma, etc. Observation group was given 2 mL budesonide suspl. by atomizing inhalation per time,twice daily for one week. Changes of serum MMP-9 and TIMP-1 levels and the ra- tio of MMP-9/TIMP-1 of patients were observed before and one week after medical treatment, and the clinical curative effect and security were estimated as well. Results After one week's medical treatment,the MMP-9 and TIMP-1 levels and the ratio of MMP-9/TIMP-1 of patients declined obviously ( P 〈 0. 05 ), and the declining rate in observation group was much higher than that of control group ( P 〈 0. 05 ). The total effective rate in observation group was much higher than that of control group( P 〈0. 05 ). No obvious drug adverse reaction(ADR) was found. Conclusion Budesonide suspl, by atomizing inhalation has reliable curative effect on COPD patients with good security, the mechanism of action has close effect on reducing the MMP-9 and TIMP-1 levels and the ratio of MMP-9/TIMP-1, and inhibition of airway remodeling.
出处
《实用药物与临床》
CAS
2013年第10期895-897,共3页
Practical Pharmacy and Clinical Remedies
基金
2012浙江省医药卫生科技项目(2012ZHB023)
关键词
慢性阻塞性肺疾病
布地奈德
基质金属蛋白酶-9
基质金属蛋白酶抑制物-1
Chronic obstructive pulmonary disease (COPD)
Budesonide
Matrix Metalloproteinase-9 ( MMP-9 )
Tissue Inhibitor of Metalloproteinase-1 ( TIMP-1 )